Skip to main content
Premium Trial:

Request an Annual Quote

CDC Validates Bioterror Reagents to Use With Cepheid Technology

NEW YORK, Dec. 10 — Cepheid announced Monday that the federal Centers for Disease Control and Prevention has developed and validated test kits to use the company's DNA detection systems to identify bioterrorism agents like anthrax.


The reagent kits are now being provided to the nationwide Laboratory Response Network, a public health network organized in 1999 to provide screening and reference testing services in case of bioterrorism attack.


These kits also include reagents to identify other pathogens beside anthrax that may be used in bioterrorism. Cepheid president and COO Kurt Petersen said that those other pathogens would remain confidential at the request of the CDC.


Cepheid's Smart Cycler line of DNA detection systems use PCR to identify samples in as little as 20 minutes. They are now being used by the CDC, the Department of Defense, the US Army Medical Research Institute and other public health and surveillance agencies.


Sunnyvale, Calif.-based Cepheid and the CDC, whose headquarters are in Atlanta, Ga., are informally working together to improve the company's prototype battery-operated portable DNA detection system, said Peterson.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.